FDA calendar places AI, rare disease policy, and aging drug review on the same week’s agenda
The FDA’s public calendar for September 27 to October 3, 2026 reads less like a routine schedule and more like a map of the agency’s current regulatory pressure points. Across a single week, senior officials are slated to appear before industry, academia, government, media, and other stakeholders on subjects ranging from artificial intelligence and rare diseases to aging, biologics, drug development, medical devices, and tobacco regulation. The calendar does not announce a new approval or enforcement action. It does reveal where the agency is investing its public attention.
A number of the meetings cluster around modernization. Jared Seehafer, identified as Deputy Commissioner for Technology and Artificial Intelligence, is scheduled to speak at the National Organization for Rare Diseases AI and Rare Diseases Roundtable. In the same week, he also has an introductory virtual meeting with a member of Congress. That pairing matters because AI in medicine now sits at the intersection of patient data, diagnostic support, therapeutic discovery, and regulatory oversight. For rare disease communities in particular, machine learning tools may shorten the path from phenotype recognition to molecular diagnosis, but only if the evidence standards are tight enough to support clinical trust.
The calendar gives that theme unusual prominence. Grace Graham, Deputy Commissioner for Policy, Legislation, and International Affairs, is scheduled for a session titled “Next Generation of American Medicines; Speaker: FDA Modernization and U.S. Competitiveness with China,” along with a biobank meeting involving Todd Golub of the Broad Institute. Those are not cosmetic speaking engagements. They point toward the policy and infrastructure questions that determine whether biomedical discovery can move from the lab to the clinic at speed, while still preserving data integrity, sample access, and regulatory accountability.
One week of meetings. Five policy fronts.
Rare disease, AI, and the problem of evidence at low prevalence
Rare disease regulation demands a different evidentiary mindset than common chronic illness. Patient numbers are small, natural history is often uneven, and endpoints may need to capture biology as much as symptoms. When AI enters that setting, the promise is not just automation; it is pattern recognition across sparse and fragmented datasets. A roundtable on AI and rare diseases therefore signals a practical question for regulators: how should algorithms be evaluated when the underlying disorders are uncommon, heterogeneous, and often underdiagnosed?
The regulatory challenge is straightforward to describe and hard to solve. AI tools can surface candidate diagnoses, harmonize imaging or genomic signals, and help stratify patients for clinical trials. They can also magnify bias when training sets overrepresent certain phenotypes, ancestral groups, or care settings. In rare disease care, even a small calibration error can misclassify patients who already face delayed diagnosis and limited treatment options. FDA leadership appearing in that forum suggests the agency is preparing to keep pace with those developments rather than react to them after they reach routine clinical use.
Karim Mikhail, Director of the Center for Biologics Evaluation and Research, is also scheduled to attend the Midsized Biotech Innovation, Policy, and Investment Summit, as well as the Make America Healthy Again Summit 2026 and an aging research discussion. CBER’s presence in those conversations fits the current biology of the field: cell therapies, gene therapies, and other biologics often mature inside small and midsized companies before scaling into broader clinical development. Regulatory predictability becomes especially important when the therapy class is complex, manufacturing-intensive, and clinically specialized.
Aging is becoming a regulatory theme, not just a demographic one
Michael Davis, Director of the Center for Drug Evaluation and Research, is listed for a Regulatory Policy with an Aging Population Meeting and for a session on modernizing drug and biologic development and review. The calendar does not spell out any specific policy change, yet the placement of aging alongside development and review is telling. Older adults are more likely to live with multimorbidity, polypharmacy, renal impairment, frailty, and altered pharmacokinetics, all of which complicate trial design and postmarket safety interpretation.
The agency’s agenda suggests a shift from treating older adults as a subgroup to treating aging as a core regulatory design issue. That affects dose selection, endpoint choice, adverse event attribution, and the generalizability of pivotal trials. In practice, a medicine that performs well in a younger cohort can behave very differently in patients with diminished physiologic reserve. Regulatory policy aimed at an aging population therefore has direct consequences for bedside prescribing, not just for conference panels.
Device innovation and public trust remain linked
Michelle Tarver, Director of the Center for Devices and Radiological Health, is scheduled to speak at the Michigan Medical Device Summit on “Advancing Innovation, Ensuring Trust.” The phrase captures a tension that defines modern device regulation. Faster iteration can improve access to sensors, software-driven diagnostics, and procedural tools, but public confidence depends on clear performance standards, postmarket surveillance, and transparent claims. Device innovation in cardiology, radiology, neurology, and digital health increasingly depends on software as much as hardware, which raises the stakes for cybersecurity, update management, and real-world validation.
This week’s schedule also includes Bret Koplow, Director of the Center for Tobacco Products, speaking at the National Association of Tobacco Outlets 25th Anniversary Conference. Even outside direct therapeutic categories, FDA’s agenda shows how broad the agency’s remit remains. Tobacco regulation still intersects with population health, prevention, and long-term disease burden, all while the agency handles questions of product standards and retail compliance.
Leadership visibility hints at where the agency expects friction
Several entries involve meetings labeled “issues of mutual interest,” introductory discussions, or speaking roles at large summits. Those labels sound generic, but in regulatory medicine they usually indicate active stakeholder management around policy direction, scientific standards, or implementation hurdles. Sean R. Keveney, Chief Counsel, has scheduled meetings involving commercial and legal stakeholders, while Donald A. Prater, Acting Deputy Commissioner for Food, is listed for an introductory meeting with Tufts University researchers and a talk at the Alliance for a Stronger FDA summit.
The FDA calendar is not clinical trial data and not a press release announcing a new review decision. It is still clinically relevant because regulation shapes what eventually reaches patients. When agency leaders devote public time to AI, rare disease infrastructure, biologics, aging, and device trust, they are signaling where future disputes, guidance documents, and evidentiary standards are likely to emerge. The most immediate question is not whether any one meeting will change practice overnight. It is whether the agency can align faster-moving technologies with the slower work of proving safety, effectiveness, and durable benefit for the patients who need them most.